北美人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型（颗粒佐剂、乳液佐剂、组合佐剂及其他）、应用（流感、肝炎、人乳头瘤病毒 (HPV) 及其他）和最终用户（制药和生物技术公司、CMO 和 CRO 及其他）划分
慢性病患病率上升推动北美人类疫苗佐剂市场
慢性病患病率上升推动了对疫苗佐剂的需求。佐剂被添加到疫苗中以增强功效和人体的免疫反应。它们通过刺激更强和更持久的免疫反应来帮助提高疫苗的有效性。随着对预防和管理慢性病的疫苗的需求不断增长，对佐剂的需求也在增加。心血管疾病、癌症、糖尿病和呼吸系统疾病等慢性疾病在全球范围内呈上升趋势。根据世界卫生组织的数据，非传染性疾病相关死亡人数最多的是心血管疾病，每年造成 1700 万人死亡，其次是癌症、慢性呼吸道疾病和糖尿病（包括与肾脏相关的死亡）。此外，根据世界心脏联合会的数据，高胆固醇每年导致 440 万人死亡，而 24% 的心血管相关死亡归因于高低密度脂蛋白 (LDL) 胆固醇。因此，慢性病负担的增加导致对可以预防或控制这些疾病的疫苗的需求不断增长。老年人口的增加也增加了对疫苗的需求。根据 NCBI 于 2023 年 1 月发布的一项研究，到 2050 年，美国 50 岁及以上人口数量将达到 2.2113 亿，较 2020 年的 1.3725 亿快速增长。50 岁及以上人群预计至少患有一种慢性病，预计到 2050 年这一数字将从 2020 年的 7152 万人增加 99.5% 至 1.4266 亿。此外，预计到 2050 年，约有 1400 万人可能患有多重疾病。肝炎的患病率也在增加。肝炎疫苗中的佐剂旨在引发强大而持久的免疫力，特别是在对标准疫苗制剂反应不佳的人群中，例如患有潜在疾病或与年龄相关的免疫衰老的人群。据世界卫生组织称，全球有超过 3.5 亿人患有乙型或丙型肝炎。在所有类型的肝炎中，有几种可以通过接种疫苗预防。根据世界卫生组织的一项研究，到 2030 年，中低收入国家估计有 450 万人通过接种疫苗可以避免因肝炎而过早死亡。因此，慢性病的日益流行推动了北美人用疫苗佐剂市场的增长。
北美人用疫苗佐剂市场概览
美国在北美人用疫苗佐剂市场占有相当大的份额。该国市场的增长主要归因于政府在医疗保健方面的支出增加以及对更有效地治疗传染病的新型疫苗制剂的需求激增。根据美国医疗保险和医疗补助服务中心的数据，2021 年美国全国医疗保健支出增长了 2.7%，达到 4.3 万亿美元或每人 12,914 美元。卫生支出占美国GDP的18.3%。根据美国卫生与公众服务部的数据，预计2019-2028年全国卫生支出将以每年5.4%的速度增长，到2028年将达到6.2万亿美元。不断上升的卫生支出可能导致用于疫苗研发的资金增加，从而刺激对人用疫苗佐剂的需求。根据2020年7月发布的全球疾病负担研究的新发现，美国的非传染性疾病和传染病负担沉重且日益加重。根据约翰霍普金斯大学的数据，过去二十年里，美国非典、莱姆病、登革热、西尼罗河病毒和寨卡病毒感染等疾病的病例迅速增加。此外，同一消息来源还证实，疟疾、肺结核、霍乱、百日咳、流感、肺炎球菌病和淋病等复发疾病的发病率有所上升。同样，根据美国疾病控制和预防中心 (CDC) 的数据，2010 年至 2022 年期间，流感每年导致 100,000 至 710,000 人住院，4,900 至 52,000 人死亡。根据 ICO/IARC 信息中心 2023 年关于 HPV 和癌症的报告，美国有 1.405 亿 15 岁及以上的女性面临患上 HPV 相关宫颈癌的风险。据预测，美国普通女性中约有 3.9% 的人会感染宫颈 HPV16/18，而 71.2% 的浸润性宫颈癌与 HPV 16 或 18 有关。因此，各种感染和复发疾病发病率的上升推动了企业在疫苗开发方面的努力，从而推动了美国北美人用疫苗佐剂市场的增长。美国政府致力于为本国医药和保健产品的开发和商业化创造有利环境。美国拥有多家潜在的制药和医疗器械市场参与者，包括辉瑞、诺华、波士顿科学、Integra LifeSciences、安进和雅培，他们拥有多项制药和医疗器械行业创新专利。因此，各制药巨头加大药物开发活动，推动了美国北美人用疫苗佐剂市场的发展。
北美人类疫苗佐剂市场收入及预测至 2030 年（百万美元）
北美人类疫苗佐剂市场细分
北美人类疫苗佐剂市场分为类型、应用、最终用户和国家。
根据类型，北美人类疫苗佐剂市场分为颗粒佐剂、乳剂佐剂、组合佐剂和其他。颗粒佐剂部分在 2022 年占据最大市场份额。
就应用而言，北美人类疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 和其他。流感细分市场在 2022 年占据了最大的市场份额。
按最终用户划分，北美人用疫苗佐剂市场细分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司细分市场在 2022 年占据了最大的市场份额。
按国家划分，北美人用疫苗佐剂市场细分为美国、加拿大和墨西哥。2022 年，美国占据了北美人用疫苗佐剂市场份额的主导地位。
Creative Biolabs Inc、Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Hawaii Biotech Inc、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是北美人用疫苗佐剂市场的主要公司。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Human Vaccine Adjuvants Market - Key Market Dynamics
4.1 North America Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market - North America Market Analysis
5.1 North America Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 North America Human Vaccine Adjuvants Market Forecast Analysis
6. North America Human Vaccine Adjuvants Market Analysis - by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Human Vaccine Adjuvants Market Analysis - by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
7.3.1 Overview
7.3.2 Human papilloma virus (HPV): North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Human Vaccine Adjuvants Market Analysis - by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Human Vaccine Adjuvants Market - Country Analysis
9.1 North America
9.1.1 North America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 US Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 US Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 US Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Canada Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 Canada Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 Canada Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Mexico Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 Mexico Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 Mexico Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Dynavax Technologies Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 CSL Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Seppic SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 SPI Pharma Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hawaii Biotech Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Croda International Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Novavax Inc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Phibro Animal Health Corp
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Creative Biolabs Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. North America Human Vaccine Adjuvants Market Segmentation
Table 2. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 16. Glossary of Terms, Human Vaccine Adjuvants Market
List of Figures
Figure 1. North America Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. North America Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. North America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
1. Creative Biolabs Inc
2. Croda International Plc
3. CSL Ltd
4. Dynavax Technologies Corp
5. Hawaii Biotech Inc
6. Novartis AG
7. Novavax Inc
8. Phibro Animal Health Corp
9. Seppic SA
10. SPI Pharma Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America human vaccine adjuvants market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America human vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.